NDA 20-457/S-003, S-004

Bristol-Myers Squibb Pharmaceutical Research Institute
Attention: Susan Behling
Associate Director, Regulatory Affairs
5 Research Parkway
P.O. Box 5100
Wallingford, CT 06492-7660

Dear Ms. Behling:

Please refer to your supplemental new drug applications dated January 29, 1998 (S-003) and November 5, 1998 (S-004), received January 30, 1998 and November 6, 1998 respectively, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Etopophos (etoposide phosphate).

These supplemental new drug applications provide for revisions in the Clinical Pharmacology and Adverse Reactions sections of the labeling. We note that S-003 was submitted as "Changes Being Effected" and is superseded by S-004.

We have completed the review of these supplemental applications and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the November 5, 1998 labeling text. Accordingly, the supplemental application S-004 is approved effective on the date of this letter. S-003 will be retained in your file.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert) submitted November 5, 1998.

Please note the following:

1. NDA 20-906 labeling should be updated with the latest labeling revisions. These revisions may be submitted as a "Changes Being Effected" supplement.

2. The following two revisions should be made at the next printing and reported in the annual report, if you are unable to incorporate them into the requested final printed labeling for this supplement:

    - The safe handling references should be updated, i.e., last reference replaced with the 1996 version.

    - Under the Dosage and Administration section, "Sterile" should be deleted from "Sterile Bacteriostatic Water for Injection with Benzyl Alcohol" per USP 25 (effective January 1, 2002).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30

days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-457/S-004." Approval of this submission by FDA is not required before the labeling is used.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Debra Vause, B.S.N., Regulatory Project Manager, at (301) 594-5724.

Sincerely,

{See appended electronic signature page}

Richard Pazdur, M.D.
Director
Division of Oncology Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Richard Pazdur

2/21/02 12:59:33 PM